ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • 2026 ACR/ARP PRSYM
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Crystal-induced arthritis"

  • Abstract Number: 2588 • ACR Convergence 2025

    Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates a Reduction in Gout Flares: Results from the Phase 3 DISSOLVE Studies

    Angelo Gaffo1, Herbert Baraf2, Anand Patel3, Tuhina Neogi4, Rehan Azeem5, Wesley DeHaan6, Ben Peace7, Hugues Santin-Janin8, Bhavisha Desai9 and Naomi Schlesinger10, 1Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, 2The Center for Rheumatology and Bone Research, Rheumatology, Wheaton, Maryland, USA; Division of Rheumatology, The George Washington University, Washington, DC, 3Conquest Research, Winter Park, FL, USA, Winter Park, FL, 4Boston University School of Medicine, Boston, MA, 5Global MACD, Sobi Inc., Waltham, MA, 6Sobi, Inc, Waltham, MA, 7Statistical Science, Sobi, Stockholm, Sweden, 8Sobi, BASEL, Switzerland, 9Sobi, Glastonbury, CT, 10Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT

    Background/Purpose: Urate-lowering therapy is recommended to lower serum urate (sUA) and for long-term prevention of gout flares (FitzGerald et al. Arthritis Care Res (Hoboken) 2020;…
  • Abstract Number: 1131 • ACR Convergence 2025

    Variant Drives Tophus Formation through Dual Mechanisms: Extracellular Aggregation andvImpaired Macrophage Phagocytic Clearance

    Yuqi wang1, Lingjiang Zhu1, Jinshuo Han2, Junbin Qian3, Martin Herrmann4, Jing Xue1 and Lei Liu1, 1The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China (People's Republic), 2Zhejiang University, School of Medicine, Hangzhou, China (People's Republic), 3Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China (People's Republic), 4University Hospital Erlangen, Erlangen, Germany

    Background/Purpose: While aggregated neutrophil extracellular traps (aggNETs) constitute the primary structural component of tophi, the susceptible population for tophaceous gout remains poorly characterized. We investigated…
  • Abstract Number: 1134 • ACR Convergence 2025

    Efficacy and Safety of Anakinra for Acute Calcium Pyrophosphate Deposition Disease Flare: A Systematic Review and Meta-Analysis

    Pannathorn Nakaphan1, Somkiat Phutinart2, Patavee Pajareya2, Priabprat Jansem3, Nattanicha Chaisrimaneepan4, Pim Jetanalin5 and Noppachai Siranart2, 1Department of Internal Medicine, Weiss Memorial Hospital, Chicago, IL, 2Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, 3Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand, 4Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, 5Department of Medicine, Division of Rheumatology, University of Illinois College of Medicine, Chicago, IL

    Background/Purpose: Calcium Pyrophosphate Deposition Disease (CPPD) is a common inflammatory arthritis among older adults. Comorbidities often limit conventional treatment of acute CPPD flare. Anakinra, an…
  • Abstract Number: 1135 • ACR Convergence 2025

    A Gain-of-Function 5’UTR Variant in ANKH Causes Familial CPPD with Elevated Extracellular PPi and Citrate

    richette pascal1, christophe Duranton2, Thomas Pinna3, Manon Ricquebourg4, LATOURTE Augustin5, Thomas Bardin6, Valérie Bousson7, Hang-Korng Ea8, Isabelle Rubera9 and Corinne Collet10, 1Rheumatology Department, Lariboisiere Hospital, Paris, Ile-de-France, France, 2CNRS-UMR 7370 - Laboratoire de Physiomedecine moléculaire, Nice, Rhone-Alpes, France, 3INSERM U1132, PARIS, Ile-de-France, France, 4Lariboisiere Hospital, INSERM U1132, Paris, France, 5Rheumatology Department, Lariboisiere Hospital, Paris, France, 6Lariboisiere Hospital, Department of Rheumatology, Paris, France, 7Radiology Department, Lariboisiere Hospital, Paris, France, 8INSERM U1132, Lariboisiere Hospital, Paris, France, 9CNRS-UMR 7370 - Laboratoire de Physiomedecine moléculaire, Nice, France, 10Reference Center for Skeletal Dysplasia, INSERM UMR 1163, Paris, France

    Background/Purpose: To identify novel pathogenic variants associated with chondrocalcinosis (CC), we systematically screened individuals with a family history of CPPD using an NGS panel. Among…
  • Abstract Number: 1136 • ACR Convergence 2025

    The Impact of Iron Overload and HFE Genetic Mutations on Joint Disease in Haemochromatosis: Data from the Haemochromatosis Arthropathy Inception Cohorts

    Bayram Farisogullari1, Pedro Machado2, Stephanie Finzel3, Graeme Carroll4, Geraldine mcCarthy5, John Stack6, Simone Parisi7, Graca Porto8, richette pascal9, Gyorgy Nagy10, Marton Weidl10, Ann Rosenthal11, Pascal Guggenbuhl12, Katarzyna Banaszkiewicz13, Barbara Butzeck14, Howard Don15, Svenja Engelhardt16, Jeremy Shearman17, David Mitchell18, Jane Barker19, Valerie Brueton19, Philip Coathup19, Jacquie Dowsett19, Marie Duncan19, Tracey Dunleavy19, Ian Fish19, Allin Hoggarth19, Mark McKinnon19, James Minter19, Tim Osborne19, Marguerite Smith19, Christine Wright19 and Patrick Kiely20, 1University College London, London, 2Department of Rheumatology, University College London, and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 3Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 4Fiona Stanley Hospital, Perth, Western Australia, Australia, 5Mater Misericordiae University Hospital, Dublin, Ireland, 6Mater Misericordiae University Hospital, Dublin, Dublin, Ireland, 7Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, 8Centro Hospitalar Universitário de Santo António, Unidade Local de Saúde de Santo António, Porto, Portugal, 9Rheumatology Department, Lariboisiere Hospital, Paris, Ile-de-France, France, 10Buda Hospital of the Hospitaller Order of Saint John of God, Budapest, Hungary, 11Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Wisconsin, 12Rennes University Hospital, Rennes, France, 13University Clinical Center in Gdańsk, Smoluchowskiego 17 Street, 80-952 Gdańsk, Poland., Gdańsk, Poland, 14European Federation of Associations of Patients with Haemochromatosis,, Croissy-sur-Seine, France, 15Haemochromatosis International, Barnstaple, United Kingdom, 16University of Freiburg, Freiburg im Breisgau, Germany, 17South Warwickshire University Foundation Trust and Warwick Medical School,, Warwick, United Kingdom, 18Clongriffin Medical Centre, Dublin, Ireland, 19c/o St George's University Hospitals NHS Trust, London, United Kingdom, 20St George's University Hospitals NHS Foundation Trust, London, United Kingdom

    Background/Purpose: A EULAR task force developed classification criteria (CC) for Haemochromatosis Arthropathy (HA) using a cohort of people with the C282Y homozygous mutation and arthropathy…
  • Abstract Number: 1138 • ACR Convergence 2025

    Efficacy of Pozdeutinurad (AR882) in Treatment Naïve and Suboptimally Treated Gouty Arthritis with Tophi

    Robert Keenan1, Puja Khanna2, Zancong Shen3, Sarah Morris3, Pamela Mundell4, Wen Wei4, Elizabeth Polvent5, Vijay Hingorani6, Shunqi Yan5 and Li-Tain Yeh7, 1Arthrosi Therapeutics, Raleigh, NC, 2Division of Rheumatology, University of Michigan, Ann Arbor, MI, 3Arthrosi therapeutics, San Diego, CA, 4Arthrosi Therapeutics Inc, San Diego, CA, 5Arthrosi Therapeutics, Inc., San Diego, CA, 6Vanguard Healthsciences, Inc., San Diego, CA, 7Arthrosi Therapeutics, Inc., Irvine, CA

    Background/Purpose: Pozdeutinurad (AR882, POZD) is a novel, selective URAT1 inhibitor currently in phase 3 clinical stage development for the treatment of gout and tophaceous gout.…
  • Abstract Number: 1103 • ACR Convergence 2024

    The Role of Renal Dual-Energy CT in Exploring the Gouty Kidney: The RENODECT Study

    Tristan Pascart1, Elie Dauphin1, Chio Yokose2, Charlotte Jauffret3, Hyon K. Choi4 and Jean-François Budzik5, 1Université Catholique de Lille, Lille, Nord-Pas-de-Calais, France, 2Massachusetts General Hospital, Boston, MA, 3Lille Catholic University, Lille, Nord-Pas-de-Calais, France, 4Massachusetts General Hospital, Lexington, MA, 5Lille Catholic University, Lille, France

    Background/Purpose: Chronic kidney disease (CKD) is a common feature in gout, and can have multiple causes, some of which are gout specific, such as gout…
  • Abstract Number: 0267 • ACR Convergence 2024

    IL-17 Participates in the Pathogenesis of Chronic Gouty Arthritis

    Hong Di1, Xinxin Han1, Yun Zhang2 and Xuejun Zeng1, 1Peking Union Medical College Hospital, Beijing, China, 2Peking Union Medical College Hospital (CAMS), Beijing, China

    Background/Purpose: Chronic gouty arthritis (CGA) is different from acute gouty arthritis  (AGA), its main characteristics include repeated or even persistent joint symptoms, tophus and bone destruction.…
  • Abstract Number: 1653 • ACR Convergence 2024

    Osteoarthritis Drives Inflammatory Imprinting of Synovial Fibroblasts, Exacerbating Gouty Arthritis Through m6A Modification of S100A4

    ZIYI CHEN1, Yinghui Hua2 and Wenjuan Wang1, 1Department of Sports Medicine, Huashan Hospital,Fudan University, Shanghai, Shanghai, China (People's Republic), 2Department of Sports Medicine, Huashan Hospital,Fudan University, Shanghai, China (People's Republic)

    Background/Purpose: Patients with osteoarthritis (OA) face an elevated risk of future gouty arthritis (GA). To delineate the underlying cellular and molecular mechanisms of OA-driven gout…
  • Abstract Number: 0270 • ACR Convergence 2024

    Longitudinal Patterns of C-Reactive Protein Values in Calcium Pyrophosphate Deposition (CPPD) Disease

    Muneet Gill, Hongshu Guan, Jamie Collins and Sara Tedeschi, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease is a crystalline arthritis affecting older adults. Systemic inflammation occurs during flares of acute calcium pyrophosphate (CPP) crystal arthritis…
  • Abstract Number: 2013 • ACR Convergence 2024

    Elevated Serum Allantoin and Allantoin/uric Acid Ratio as Indicators of Oxidative Stress in Severe Gout and Cardiovascular Comorbidities

    Lenka Hasikova1, Petr Kozlik2, Kveta Kalikova3, Petr Dusek4, Marketa Pavlikova1, Blanka Stiburkova5 and Jakub Závada6, 1Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 2Department of Analytical Chemistry, Faculty of Science, Charles University, Prague, Czech Republic, Prague, Czech Republic, 3Department of Physical and Macromolecular Chemistry, Faculty of Science, Charles University, Prague, Czech Republic, Prague, Czech Republic, 4Department of Neurology and Centre of Clinical Neuroscience and Department of Radiology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic, Prague, Czech Republic, 5Institute of Rheumatology, Prague, Czech Republic and Department of Paediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic, Prague, Czech Republic, 6Institute of Rheumatology and Charles University, Praha, Czech Republic

    Background/Purpose: Uric acid (UA) can be non-enzymatically oxidized into allantoin and other products by reactive oxygen species under conditions of increased oxidative stress. Consequently, allantoin…
  • Abstract Number: 0272 • ACR Convergence 2024

    Calcifications of the Transverse Ligament of the Atlas in Patients Diagnosed with Calciumpyrophosphate Crystal Arthritis – a Retrospective Observational Study

    Shay Brikman1, Noga Shabshin2 and Amir Bieber3, 1Emek Medical Center, Afula, Israel, 2Emek Medical Center, Clalit Health Services, Afula, Israel, 3Emek Medical Center, Clalit Health Services, Raanana, Israel

    Background/Purpose: Chondrocalcinosis (CC) is commonly detected on X-ray films of the knee, wrist, and symphysis pubis. Calcium pyrophosphate (CPP) deposition disease is sometimes associated with…
  • Abstract Number: 2016 • ACR Convergence 2024

    Treat to Target in Gout Yields Superior Outcomes Compared to Treat to Avoid Symptoms Approach (results from the Gout TrEatment Strategy Overture Trial)

    Anusha Moses1, Martijn Oude Voshaar1, Tim L.Th. Jansen2 and Mart Van De Laar1, 1University of Twente, Enschede, The Netherlands, Enschede, Overijssel, Netherlands, 21VieCuri Medisch Centrum, Venlo, Netherlands

    Background/Purpose: Both the European League Against Rheumatism (EULAR) and the American College for Rheumatology (ACR) state that gout can be effectively managed by reducing sUA…
  • Abstract Number: 0276 • ACR Convergence 2024

    Exploring the Prevalence of Crowned Dens Syndrome in a Polymyalgia Rheumatica Veterans Affairs Patient Cohort

    Marlene Marte Furment1, Binod Kc1, Bhavya Poudyal1, Aakritee Sharma Subedi2, Mahnoor Sherazi3, Jihad Ben Gabr1, Shveta Trikha4, Brian Cooney5 and Fatme Allam5, 1SUNY Upstate Medical University, Syracuse, NY, 2SUNY Upstate University Hospital, Syracuse, 3State University of New York, Syracuse, NY, 4Syracuse VA Medical Center, Syracuse, 5Syracuse VA Medical Center, Syracuse, NY

    Background/Purpose: Crowned Dens (CD) is the radiological finding of calcium pyrophosphate dihydrate (CPPD) crystal deposition in the cruciform and alar ligaments giving the appearance of…
  • Abstract Number: 2219 • ACR Convergence 2024

    Association of Chondrocalcinosis with Disease Activity and Drug Response in Rheumatoid Arthritis: Baseline Characteristics of the Swiss Rheumatoid Arthritis Outcomes Cohort

    Tobias Manigold1, Nicolas Bodmer2, Rosoux Elisabeth3, Deborah Markham4, Guillaume Fahrni3, Raphael Micheroli5, Lucas Bachmann2, Jonas Brändli6, Fabio Becce7 and Thomas Hügle8, 1Department of Rheumatology, Inselspital University Hospital Bern, Bern, Switzerland., Bern, Switzerland, 2Medignition, Zürich, Switzerland, 33) Department of Radiology, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland, Lausanne, Switzerland, 4Department of Rheumatology, University Hospital Lausanne (CHUV), Switzerland, Lausanne, Switzerland, 5University Hospital Zurich, Zurich, Switzerland, 66) Data Science Team, Swiss Clinical Quality Management Foundation, Zurich, Switzerland, Zürich, Switzerland, 7Lausanne University Hospital (CHUV), Lausanne, Switzerland, 8Lausanne University Hospital, Lausanne, Switzerland

    Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) disease can mimic or interfere with the course of rheumatoid arthritis (RA). Previous studies suggest higher prevalence of Chondrocalcinosis…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology